Across rheumatic diseases

Reference intervals of work ability and productivity loss and their use in patients with inflammatory rheumatic and musculoskeletal diseases

RMD OpenPublished Cross-sectional study

Authors' conclusion

Work ability and productivity are not perfect in the general population, based on the newly developed RIs for the three work outcomes.

Study context

Population
Patients with inflammatory rheumatic and musculoskeletal disease (iRMDs) and population controls without iRMDs having paid work, participating in a Dutch cohort study413 controls
Exposure
Patients with iRMDs vs population controls without iRMDs
  • Controlsn = 413reference
Outcome
Reference intervals for work ability (0-10), at-work productivity loss and overall productivity loss (0%-100%) in the general working population
Methodological detailsgeneralised additive model for location, shape and scale parameters, age-specific reference intervals (RIs) and percentile curves
  • Generalised additive model for location, shape and scale parameters
  • Age-specific RIs and percentile curves

Main finding

As reported in the abstract

Work outcomes in controls
GroupValueAt-work productivity loss, mean (SD)Overall work productivity loss, mean (SD)
Controlsmean 8.7 (SD 1.6)6.3% (7.2)11% (25.6)

Controls

Valuemean 8.7 (SD 1.6)
At-work productivity loss, mean (SD)6.3% (7.2)
Overall work productivity loss, mean (SD)11% (25.6)
Work ability 95% RI, age 22 to 29 years
5.9-10
Work ability 95% RI, age 50 to 59 years
4.9-9.1

Observational data: associations, not effects.

Further findings

Patients had worse work outcomes than controls, especially for at-work and overall productivity loss

Original publication

Reference intervals of work ability and productivity loss and their use in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. Published 6 January 2025. doi:10.1136/rmdopen-2024-004877

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.